Literature DB >> 35462659

Prognostic Roles of ZNF703 and SMAD4 Expression in Patients with Papillary Thyroid Cancer and Association with Nodal Metastasis.

Asmaa Hussein Mohamed1, Ola A Harb1, Shereen El Shorbagy2, Rawda Balata3, Mohamed Farouk Amin4, Osama Abd-Elaziz4.   

Abstract

It is important to detect novel predictive biomarkers of cervical lymph node metastasis (CLNM) in papillary thyroid carcinoma (PTC) to help the surgeons in making early decision of performing central lymph node dissection and aggressive management strategies in selected high-risk patients, thus improving their prognosis. Zinc finger protein 703 (ZNF703) is a member of the neutrophil extracellular trap (NET) transcription factors family which has roles in proliferation and invasion of cancer cells. SMAD4 is a protein that has a role in cellular processes including cell proliferation, invasion, and metastasis through many genes' transcription. In this study, we aimed to assess the expression of ZNF703 and SMAD4 in PTC and evaluated the correlation between its expression, clinicopathological features of PTC cases, and prognostic parameters of patients to evaluate their roles in PTC progression. This is a retrospective study which included 40 cases with PTC. For immunohistochemistry, tissues stained their paraffin blocks with ZNF703 and SMAD4. We followed patients to detect disease progression and recurrence. Positive ZNF703 expression and negative SMAD4 expression were associated with higher incidence of CLNM, advanced stage and large tumor size, higher incidence of disease progression, recurrence, unfavorable PFS, and unfavorable OS rates. The higher ZNF703 expression and the lower SMAD4 expression were significantly increased in PTC patients with cervical LNM compared with those without. ZNF703 over expression and downregulation SMAD4 expression was significantly increased in PTC patients. Elevated expression of ZNF703 in tumor tissue with CLNM can be considered a predictive factor for the development of metastasis.
© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  Immunohistochemistry; Papillary thyroid cancer; Prognosis; ZNF703 and SMAD4

Year:  2022        PMID: 35462659      PMCID: PMC8986956          DOI: 10.1007/s13193-022-01519-5

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  22 in total

1.  MKL1 overexpression predicts poor prognosis in patients with papillary thyroid cancer and promotes nodal metastasis.

Authors:  Xian Cheng; Shichen Xu; Jie Pan; Jiangxia Zheng; Xiaowen Wang; Huixin Yu; Jiandong Bao; Yong Xu; Haixia Guan; Li Zhang
Journal:  J Cell Sci       Date:  2019-08-22       Impact factor: 5.285

2.  Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.

Authors:  Margaret M Kozak; Rie von Eyben; Jonathan Pai; Stephen R Vossler; Maneesha Limaye; Priya Jayachandran; Eric M Anderson; Jenny L Shaffer; Teri Longacre; Reetesh K Pai; Albert C Koong; Daniel T Chang
Journal:  J Clin Pathol       Date:  2015-02-13       Impact factor: 3.411

3.  microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor.

Authors:  Cheng-Bi Xu; Xue-Shi-Bo-Jie Liu; Jin-Qiu Li; Xue Zhao; Ding Xin; Dan Yu
Journal:  J Cell Biochem       Date:  2019-01-31       Impact factor: 4.429

4.  Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.

Authors:  A R Garcia-Rendueles; J S Rodrigues; M E R Garcia-Rendueles; M Suarez-Fariña; S Perez-Romero; F Barreiro; I Bernabeu; J Rodriguez-Garcia; L Fugazzola; T Sakai; F Liu; J Cameselle-Teijeiro; S B Bravo; C V Alvarez
Journal:  Oncogene       Date:  2016-07-25       Impact factor: 9.867

5.  ZNF703 is Overexpressed in Papillary Thyroid Carcinoma Tissues and Mediates K1 Cell Proliferation.

Authors:  Xiaolin Yang; Geling Liu; Luyang Zang; Ding Li; Fang Yu; Xiuxiu Xiang; Weijuan Li
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

6.  The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.

Authors:  Steffen Ormanns; Michael Haas; Anna Remold; Stephan Kruger; Stefan Holdenrieder; Thomas Kirchner; Volker Heinemann; Stefan Boeck
Journal:  Int J Mol Sci       Date:  2017-05-19       Impact factor: 5.923

7.  Overexpression of ZNF703 facilitates tumorigenesis and predicts unfavorable prognosis in patients with cholangiocarcinoma.

Authors:  Keyu Li; Jiabei Wang; Jihua Han; Yaliang Lan; Changming Xie; Shangha Pan; Lianxin Liu
Journal:  Oncotarget       Date:  2016-11-15

8.  MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells.

Authors:  Xiaoping Zhang; Lin Liu; Xianzhao Deng; Dan Li; Haidong Cai; Yushui Ma; Chengyou Jia; Bo Wu; Youben Fan; Zhongwei Lv
Journal:  Oncogene       Date:  2018-08-31       Impact factor: 9.867

9.  Immunohistochemical Expression of TGF-Β1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer.

Authors:  Koni Ivanova; Irena Manolova; Maria-Magdalena Ignatova; Maya Gulubova
Journal:  Open Access Maced J Med Sci       Date:  2018-03-02

10.  SMAD4 activates Wnt signaling pathway to inhibit granulosa cell apoptosis.

Authors:  Xing Du; Qiqi Li; Liu Yang; Lu Liu; Qiuyu Cao; Qifa Li
Journal:  Cell Death Dis       Date:  2020-05-15       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.